Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2023 Jan 8

PMID 36611440

Authors

Davide Norata

Marta Peri

Giuseppe Roberto Giammalva

Antonino Lupica

Federica Paolini

Lorena Incorvaia

Giuseppe Badalamenti

Valerio Gristina

Antonio Galvano

Antonio Russo

Domenico Gerardo Iacopino

Mauro Silvestrini

Viviana Bazan

Filippo Brighina

Vincenzo Di Stefano

Affiliations

Soon will be listed here.

Abstract

Von Hippel-Lindau (VHL) disease is an autosomal dominant condition that predisposes affected individuals to a variety of malignant and benign neoplasms. The pathogenetic turning point of this illness is the accumulation of hypoxia-inducible factor (HIF)-1α, a transcription factor of several genes involved in oncogenesis, angiogenesis, tissue regeneration, metabolic regulation, hematopoiesis, and inflammatory responses. From an oncological perspective, increased awareness of the molecular pathways underlying this disease is bringing us closer to the development of specific and targeted therapies. Meanwhile, on the surgical side, improved understanding can help to better identify the patients to be treated and the surgical timing. Overall, pathogenesis research is crucial for developing patient-tailored therapies. One of the actual key topics of interest is the link between the VHL/HIF axis and inflammation. The present study aims to outline the fundamental mechanisms that link VHL disease and immune disorders, as well as to explore the details of the overlap between VHL disease and myasthenia gravis (MG) pathogenetic pathways. As a result, MG becomes a paradigm for autoimmune disorders that might be related with VHL disease.

Citing Articles

Thymic gene expression analysis reveals a potential link between HIF-1A and Th17/Treg imbalance in thymoma associated myasthenia gravis.

Altinonder I, Kaya M, Yentur S, Cakar A, Durmus H, Yegen G J Neuroinflammation. 2024; 21(1):126.

PMID: 38734662 PMC: 11088784. DOI: 10.1186/s12974-024-03095-7.

Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis.

Martin-Gutierrez L, Waddington K, Maggio A, Coelewij L, Oppong A, Yang N Clin Exp Immunol. 2024; 217(2):204-218.

PMID: 38625017 PMC: 11239565. DOI: 10.1093/cei/uxae032.

When rare diseases crisscross within the same patient: von Hippel-Lindau and type 1 gastric neuroendocrine tumor.

Alexandraki K, Spyroglou A, Xekouki P, Bramis K, Kyriakopoulos G, Barkas K Hormones (Athens). 2024; 23(3):585-590.

PMID: 38619811 PMC: 11436398. DOI: 10.1007/s42000-024-00556-9.

Transient Neonatal Myasthenia Gravis Born to a Mother with Asymptomatic MG: A Case Report.

Yang J, Pan L, Liu Y, Wang Y Degener Neurol Neuromuscul Dis. 2024; 14:15-19.

PMID: 38444566 PMC: 10913793. DOI: 10.2147/DNND.S451611.

Stereotypic T cell receptor clonotypes in the thymus and peripheral blood of Myasthenia gravis patients.

Lee Y, Kim S, Lee E, Shin H, Kim M, Lee C Heliyon. 2024; 10(4):e26663.

PMID: 38420468 PMC: 10901099. DOI: 10.1016/j.heliyon.2024.e26663.

References

Evans D, Howard E, Giblin C, Clancy T, Spencer H, Huson S . Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010; 152A(2):327-32. DOI: 10.1002/ajmg.a.33139. View

Jonasch E, Donskov F, Iliopoulos O, Rathmell W, Narayan V, Maughan B . Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021; 385(22):2036-2046. PMC: 9275515. DOI: 10.1056/NEJMoa2103425. View

Schaffert H, Pelz A, Saxena A, Losen M, Meisel A, Thiel A . IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis. Eur J Immunol. 2015; 45(5):1339-47. DOI: 10.1002/eji.201445064. View

OConnor Jr W, Zenewicz L, Flavell R . The dual nature of T(H)17 cells: shifting the focus to function. Nat Immunol. 2010; 11(6):471-6. DOI: 10.1038/ni.1882. View

Li Q, Li D, Zhang X, Wan Q, Zhang W, Zheng M . E3 Ligase VHL Promotes Group 2 Innate Lymphoid Cell Maturation and Function via Glycolysis Inhibition and Induction of Interleukin-33 Receptor. Immunity. 2018; 48(2):258-270.e5. PMC: 5828523. DOI: 10.1016/j.immuni.2017.12.013. View

Roche J, Capablo J, Larrad L, Gervas-Arruga J, Ara J, Sanchez A . Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve. 2011; 44(2):278-80. DOI: 10.1002/mus.22070. View

Le Moan N, Baeten K, Rafalski V, Ryu J, Rios Coronado P, Bedard C . Hypoxia Inducible Factor-1 in Astrocytes and/or Myeloid Cells Is Not Required for the Development of Autoimmune Demyelinating Disease. eNeuro. 2015; 2(2). PMC: 4511492. DOI: 10.1523/ENEURO.0050-14.2015. View

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

Dang E, Barbi J, Yang H, Jinasena D, Yu H, Zheng Y . Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell. 2011; 146(5):772-84. PMC: 3387678. DOI: 10.1016/j.cell.2011.07.033. View

10.

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

11.

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

12.

Palazon A, Goldrath A, Nizet V, Johnson R . HIF transcription factors, inflammation, and immunity. Immunity. 2014; 41(4):518-28. PMC: 4346319. DOI: 10.1016/j.immuni.2014.09.008. View

13.

Jensen G, Mortensen M, Kloppel G, Bruun Nielsen M, Nielsen O, Detlefsen S . Utility of pVHL, maspin, IMP3, S100P and Ki67 in the distinction of autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Pathol Res Pract. 2020; 216(5):152925. DOI: 10.1016/j.prp.2020.152925. View

14.

Zhang Y, Zhang Y, Gu W, He L, Sun B . Th1/Th2 cell's function in immune system. Adv Exp Med Biol. 2014; 841:45-65. DOI: 10.1007/978-94-017-9487-9_3. View

15.

Chen Y, Gaber T . Hypoxia/HIF Modulates Immune Responses. Biomedicines. 2021; 9(3). PMC: 8000289. DOI: 10.3390/biomedicines9030260. View

16.

Louise M Binderup M, Smerdel M, Borgwadt L, Beck Nielsen S, Madsen M, Moller H . von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. Eur J Med Genet. 2022; 65(8):104538. DOI: 10.1016/j.ejmg.2022.104538. View

17.

Wanebo J, Lonser R, Glenn G, Oldfield E . The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg. 2003; 98(1):82-94. DOI: 10.3171/jns.2003.98.1.0082. View

18.

Abbott R, Thayer M, Labuda J, Silva M, Philbrook P, Cain D . Germinal Center Hypoxia Potentiates Immunoglobulin Class Switch Recombination. J Immunol. 2016; 197(10):4014-4020. PMC: 5123804. DOI: 10.4049/jimmunol.1601401. View

19.

Rodriguez-Perea A, Arcia E, Rueda C, Velilla P . Phenotypical characterization of regulatory T cells in humans and rodents. Clin Exp Immunol. 2016; 185(3):281-91. PMC: 4991523. DOI: 10.1111/cei.12804. View

20.

Knudson Jr A . Genetics of human cancer. Annu Rev Genet. 1986; 20:231-51. DOI: 10.1146/annurev.ge.20.120186.001311. View